Hospital EBITDA Impact: India’s Cancer Drug Margin Cap
Hospital EBITDA impact of India’s 30% cancer drug margin cap: the estimate, assumptions to question and key dates, 27 October and 9 November.
Hospital EBITDA Impact: India’s Cancer Drug Margin Cap
Hospital EBITDA impact of India’s 30% cancer drug margin cap: the estimate, assumptions to question and key dates, 27 October and 9 November.
Indian Hospital IPOs: Paras Health Issue in Context
Indian hospital IPOs: Paras Health’s ₹1,450 crore issue, debt-repayment plan, anchor round and expansion, with risks and open questions.
OpenAI Life Sciences AI: Orchestra Bio Deal and Rosalind
OpenAI life sciences AI adds Orchestra Bio’s R&D coordination team. What Rosalind covers, what was not disclosed and what to watch.
Ebola Outbreak Africa: Nigeria Becomes Fifth Country
Ebola outbreak Africa update: Nigeria confirms an imported case in Abuja, the fifth country affected. What WHO says and what is still unknown.
Bepirovirsen FDA Approval: GSK, Ionis and the Market
Bepirovirsen FDA approval gives GSK a first-in-class hepatitis B drug. See the designations, Ionis royalties, companion test and what is undisclosed.
GLP-1 Beauty Market: Brands Test Skin-Change Products
GLP-1 beauty market: L’Oréal, Natura and Galderma are testing products for weight-loss skin changes. See the forecasts and open questions.
Toripalimab India Approval: Dr Reddy’s Second Indication
Toripalimab India approval: Dr. Reddy’s adds esophageal cancer to Zytorvi’s label. What the data show and what price and launch details are missing.
Measles Vaccination: What 4,410 US Cases Mean for Families
Measles vaccination guidance as US cases hit 4,410: CDC says two MMR doses are 97% effective. What Pennsylvania and the CDC advise families.
Gilead Ulcerative Colitis Drug: Phase 3 Planned for 2027
Gilead ulcerative colitis drug emvistegrast met its Phase 2 goal; Phase 3 is planned for 2027 and combinations are in view. What is and is not known.
